Cellectis S.A. - American Depositary Shares — Rendiconto Finanziario (NASDAQ:CLLS) | MetaTrader

Apri il grafico completo

Cellectis S.A. - American Depositary Shares

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

Notizie

Rating outperform confermato per Cellectis su piattaforma allogenica

Citizens conferma il rating su Cellectis per i progressi CAR-T

Cellectis supera le previsioni del Q4 2025, titolo in rialzo

Gli EPS di Cellectis hanno battuto le aspettative per 0,10$, il fatturato supera le previsioni

Jefferies avvia copertura su Cellectis con rating Buy

Jefferies assumes coverage on Cellectis stock with Buy rating

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Brunswick (NYSE:BC), Cellectis (NASDAQ:CLLS)

Clear Street inizia la copertura di Cellectis con rating Buy sul potenziale CAR-T

Clear Street initiates Cellectis stock with Buy rating on CAR-T potential

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This (CLLS)

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Allogene Therapeutics (NASDAQ:ALLO), Cellectis (NASDAQ:CLLS)

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Argo Blockchain (NASDAQ:ARBK), Ascent Solar Technologies (NASDAQ:ASTI)